Лечение тромбоза глубоких вен с использованием перорального ингибитора тромбина

the tolerance to dabigatran etexilate and the patients’ compliance with the prescribed treatment were estimated. Results. None of the patient exhibited the signs of recurrent venous thromboembolism (95% confidence interval 0—14.6%). Hemorrhagic episodes during the 3 month observation period were recorded in 4 (12.5%) patients (95% confidence interval 4—30%). The cases of severe hemorrhage were totally absent. Only one (3%) patient developed an adverse reaction (tachycardia). Compliance with the prescribed therapy was estimated at 94%. Conclusion. The application of dabigatran etexilate in the routine clinical practice has excellent prospects due to its high effectiveness and safety for the patients presenting with deep venous thrombosis.